Effect of different polymers and their combinations on the release of metoclopramide HCl from sustained-release hydrophilic matrix tablets

Pharmaceutical Development and Technology

Volumn 18, Issue 5, 2013, Pages 1122-1130

  Savaşer, Ayhan ^a   Taş, Çetin ^a   Bayrak, Ziya ^a   Özkan, Cansel Köse ^a   Özkan, Yalçín ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Chitosan; HPMC; Matrix tablets; Metoclopramide HCl; Sustained release

Indexed keywords

CARBOMER; CARBOXYMETHYLCELLULOSE; CHITOSAN; HYDROXYPROPYLMETHYLCELLULOSE; METOCLOPRAMIDE; POLYMER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; HYDROPHILICITY; INFRARED SPECTROSCOPY; MATRIX TABLET; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TABLET COMPRESSION;

ACRYLIC RESINS; CARBOXYMETHYLCELLULOSE SODIUM; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; METOCLOPRAMIDE; POLYMERS; SOLUBILITY; TABLETS;

EID: 84887414655     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.710240     Document Type: Article

References (39)

1. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983;25:451-494.
2. American Hospital Formulary Service. Drug Information. (1989). Bethesda, MD: American Society of Hospital Pharmacists, Inc., p 1622.
3. Martindale's Extra Pharmacopoeia. (2002). In: Reynolds JR, Ed. 33rd Edition, The Complete Drug Reference. pp 1235.
4. st communication: single dose study. Arzneimittelforschung 1987;37:221-224.
5. nd communication: multiple dose study. Arzneimittelforschung 1987;37:224-228.
6. Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet 1983;8:523-529.
7. Hasan EI, Amro BI, Arafat T, Badwan AA. Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl. Eur J Pharm Biopharm 2003;55:339-344.
8. Bernardo-Escudero R, Alonso-Campero R, de Jesús Francisco-Doce MT, Cortés-Fuentes M, Villa-Vargas M, Angeles-Uribe J. Comparison of the pharmacokinetics of a new 15-mg modifed-release tablet formulation of metoclopramide versus a 10-mg immediate-release tablet: a single-and multiple-dose, randomized, open-label, parallel-group study in healthy Mexican male volunteers. Clin Ter 2011;33:630-643.
9. Conti S, Maggi L, Segale L, Ochoa Machiste E, Conte U, Grenier P et al. Matrices containing NaCMC and HPMC 2. Swelling and release mechanism study. Int J Pharm 2007;333:143-151.
10. Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm 2001;52:75-82.
11. Corti G, Cirri M, Maestrelli F, Mennini N, Mura P. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-beta-cyclodextrin. Eur J Pharm Biopharm 2008;68:303-309.
12. Varshosaz J, Tavakoli N, Eram SA. Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets. Drug Deliv 2006;13:113-119.
13. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983;15:25-35.
14. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Rel 1987;5:37-42.
15. ICH Topic Q2 (R1), Validation of Analytical Procedures: Text and Methodology 1996.
16. Chien YW. (1997). Novel drug delivery systems. 2nd ed. Marcel Dekker, New York, pp. 1-42.
17. United States Pharmacopeia-USP31-USP26, 2010, USP, Rockville.
18. Lin SY, Wang SL. Advances in simultaneous DSC-FTIR microspectroscopy for rapid solid-state chemical stability studies: some dipeptide drugs as examples. Adv Drug Deliv Rev 2012;64:461-478.
19. Wang S-L, Wong Y-C, Cheng W-T, Lin S-Y. A continuous process for solid-state dehydration, amorphization and recrystallization of metoclopramide HCl monohydrate studied by simultaneous DSC-FTIR microspectroscopy. J Term Anal Calorim 2011;104:261-264.
20. Patel GM, Patel MM. Compressed matrix dual-component vaginal drug delivery system containing metoclopramide hydrochloride. Acta Pharm 2009;59:273-288.
21. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 2001;73:121-136.
22. Arno EA, Anand P, Bhaskar K, Ramachandran S, Saravanan M, Vinod R. Eudragit NE30D based metformin/gliclazide extended release tablets: formulation, characterisation and in vitro release studies. Chem Pharm Bull 2002;50:1495-1498.
23. Nerurkar J, Jun HW, Price JC, Park MO. Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates. Eur J Pharm Biopharm 2005;61:56-68.
24. Patel H, Panchal D, Patel U, Brahmbhatt T, Suthar M. Matrix Type Drug Delivery System: A Review. JPSBR 2011;1:143-151.
25. Kose-Ozkan C, Savaser A, Tas C, Ozkan Y. The development and in vitro evaluation of sustained release tablet formulations of benzydamine hydrochloride and its determination. Comb Chem High Troughput Screen 2010;13:683-689.
26. Lee BJ, Ryu SG, Cui JH. Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev Ind Pharm 1999;25:493-501.
27. Ribeiro L, Ferreira DC, Veiga FJ. In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. J Control Release 2005;103:325-339.
28. Park SH, Chun MK, Choi HK. Preparation of an extended-release matrix tablet using chitosan/Carbopol interpolymer complex. Int J Pharm 2008;347:39-44.
29. Betageri GV, Deshmukh DV, Gupta RB. Oral sustained-release bioadhesive tablet formulation of didanosine. Drug Dev Ind Pharm 2001;27:129-136.
30. Jelena P, Djuric Z, Jovanovic M, Ibric S, Kilibarda V, Jovanovic D et al. Biopharmaceutical characterization of sustained release matrix tablets based on novel carbomer polymers: formulation and in vivo investigation. Eur J Drug Metab Pharmacokinet 2005;30:99-104.
31. Tas C, Ozkan Y, Savaser A, Baykara T. In vitro and ex vivo permeation studies of chlorpheniramine maleate gels prepared by carbomer derivatives. Drug Dev Ind Pharm 2004;30:637-647.
32. Garcia O, Blanco MD, Martin JA, Teijon JM. 5-Fluorouracil trapping in poly(2-hydroxyethyl methacrylate-co-acrylamide) hydrogels: in vitro drug delivery studies. Eur J Polym 2000, 36:111-122.
33. Abdel-Rahman SI, Gamal MM, El-Badry M. Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets. Saudi Pharm J 2009, 17:283-288.
34. Hussain AS, Johnson RD, Shivanand P, Zoglio MA. Polymer on drug release from hydrophilic matrix capsules. Drug Dev Ind Pharm. 1994;20:2645-2657.
35. Bodea A, Leucuta SE. Optimization of hydrophilic matrix tablets using a D-optimal design. Int J Pharm 1997;153:247-255.
36. Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release 2011;154:2-19.
37. Singh J, Gupta S, Kaur H. Prediction of in vitro drug release mechanisms from extended release matrix tablets using SSR/R2 Technique. Trends in App Sci Res 2011;6:400-409.
38. Kabir AKL, Jesmeen T, Biswas BK, Rouf ASS. Formulation and in vitro evaluation of esomeprozale magnesium hydrophilic matrix SR tablet. Turk J Pharm Sci 2009;6:1-10.
39. Dabbagh MA, Ford JL, Rubinstein MH, Hogan JE, Rajabi-Siahboomi AR. Release of propranolol hydrochloride from matrix tablets containing sodium carboxymethylcellulose and hydroxypropylmethylcellulose. Pharm Dev Technol 1999;4:313-324.